Biogen (NASDAQ: BIIB) recently received a number of ratings updates from brokerages and research firms:

  • 3/20/2017 – Biogen was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $310.17 price target on the stock.
  • 3/16/2017 – Biogen was downgraded by analysts at Leerink Swann from an “outperform” rating to a “market perform” rating. They now have a $300.00 price target on the stock.
  • 3/16/2017 – Biogen was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $305.00 price target on the stock, down previously from $369.00.
  • 3/7/2017 – Biogen had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $290.00 price target on the stock.
  • 3/1/2017 – Biogen is now covered by analysts at Instinet. They set a “buy” rating and a $345.00 price target on the stock.
  • 3/1/2017 – Biogen is now covered by analysts at Nomura. They set a “neutral” rating on the stock.
  • 2/24/2017 – Biogen had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $310.00 price target on the stock.
  • 2/21/2017 – Biogen was upgraded by analysts at TheStreet from a “c+” rating to a “b-” rating.
  • 2/11/2017 – Biogen was given a new $296.00 price target on by analysts at Credit Suisse Group AG. They now have a “hold” rating on the stock.
  • 2/7/2017 – Biogen was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $295.39 price target on the stock.
  • 2/7/2017 – Biogen had its “hold” rating reaffirmed by analysts at Robert W. Baird.
  • 2/7/2017 – Biogen was upgraded by analysts at Citigroup Inc from a “neutral” rating to a “buy” rating. They now have a $305.00 price target on the stock.
  • 2/6/2017 – Biogen was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $309.75 price target on the stock.
  • 2/6/2017 – Biogen had its “sell” rating reaffirmed by analysts at Mizuho.
  • 2/4/2017 – Biogen was given a new $296.00 price target on by analysts at Credit Suisse Group AG. They now have a “hold” rating on the stock.
  • 2/2/2017 – Biogen had its “buy” rating reaffirmed by analysts at Royal Bank of Canada.
  • 1/30/2017 – Biogen was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $309.75 price target on the stock.
  • 1/30/2017 – Biogen had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $360.00 price target on the stock.
  • 1/27/2017 – Biogen had its price target raised by analysts at Morgan Stanley from $353.00 to $369.00. They now have an “overweight” rating on the stock.
  • 1/26/2017 – Biogen was given a new $293.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 1/24/2017 – Biogen was given a new $314.00 price target on by analysts at Credit Suisse Group AG. They now have a “hold” rating on the stock.
  • 1/24/2017 – Biogen had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $313.00 price target on the stock.
  • 1/24/2017 – Biogen had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $336.00 price target on the stock.

Shares of Biogen Inc (NASDAQ:BIIB) traded down 0.47% on Monday, reaching $274.80. 1,654,081 shares of the company’s stock traded hands. Biogen Inc has a one year low of $223.02 and a one year high of $333.65. The company’s 50-day moving average price is $283.74 and its 200 day moving average price is $293.74. The firm has a market cap of $59.34 billion, a P/E ratio of 16.23 and a beta of 0.72.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Thursday, January 26th. The biotechnology company reported $5.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.96 by $0.08. The firm earned $2.87 billion during the quarter, compared to analyst estimates of $2.94 billion. Biogen had a net margin of 32.34% and a return on equity of 38.48%. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the business posted $4.50 EPS. On average, equities analysts forecast that Biogen Inc will post $20.94 EPS for the current fiscal year.

In other Biogen news, VP Paul J. Clancy sold 9,891 shares of the stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $291.55, for a total value of $2,883,721.05. Following the completion of the sale, the vice president now owns 20,705 shares in the company, valued at approximately $6,036,542.75. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michel Vounatsos acquired 1,333 shares of the firm’s stock in a transaction on Monday, February 27th. The stock was purchased at an average price of $285.39 per share, with a total value of $380,424.87. The disclosure for this purchase can be found here. Company insiders own 0.32% of the company’s stock.

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

5 Day Chart for NASDAQ:BIIB

Receive News & Ratings for Biogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.